{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:18:35Z","timestamp":1783423115147,"version":"3.54.6"},"reference-count":119,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cancer Research UK (CRUK) Programme Foundation Award","award":["DRCPFA-Nov21\\100001"],"award-info":[{"award-number":["DRCPFA-Nov21\\100001"]}]},{"DOI":"10.13039\/501100001273","name":"Children with Cancer UK","doi-asserted-by":"crossref","award":["2014\/170"],"award-info":[{"award-number":["2014\/170"]}],"id":[{"id":"10.13039\/501100001273","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br. J. Hosp. Med. (Lond)"],"abstract":"<jats:p>Methotrexate is a highly effective anti-folate drug, used for a range of oncological and inflammatory conditions. Toxic effects of methotrexate on the bone marrow, mucosa, liver and kidneys are widely appreciated; however, clinicians may be less familiar with neurotoxic side-effects. Neurotoxicity is primarily reported in those receiving high-dose or intrathecal methotrexate; however, it may occur in patients receiving low-dose treatment. Symptoms range from acute headache\/somnolence, sub-acute onset of seizures\/stroke-like symptoms, to long-term cognitive and behavioural difficulties. Stroke-like symptoms occur several days after administration when the patient may be out of the hospital, meaning that acute care providers must be able to recognise and appropriately manage these conditions. The mechanism by which methotrexate causes neurotoxicity remains poorly understood, and although some treatments and preventative agents have been identified, they lack robust evidence at present, representing a key area for future research. This article aims to provide a state-of-the-art review of methotrexate neurotoxicity, which will increase physician awareness of this condition, its presentation, and to highlight evidence and research gaps relating to treatment and prevention.<\/jats:p>","DOI":"10.31083\/bjhm55135","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:55:28Z","timestamp":1783421728000},"source":"Crossref","is-referenced-by-count":0,"title":["Methotrexate Neurological Toxicities: Current State-of-the-Art"],"prefix":"10.31083","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4362-0621","authenticated-orcid":true,"given":"Abbie","family":"Wilson","sequence":"first","affiliation":[{"name":"School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, G61 1QH Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-5246","authenticated-orcid":true,"given":"Christina","family":"Halsey","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, G61 1QH Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. The New England Journal of Medicine. 1948; 238: 787\u2013793.","DOI":"10.1056\/NEJM194806032382301"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hamed KM, Dighriri IM, Baomar AF, Alharthy BT, Alenazi FE, Alali GH, et al. Overview of Methotrexate Toxicity: A Comprehensive Literature Review. Cureus. 2022; 14: e29518.","DOI":"10.7759\/cureus.29518"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Lipscomb GH. Medical therapy for ectopic pregnancy. Seminars in Reproductive Medicine. 2007; 25: 93\u201398.","DOI":"10.1055\/s-2007-970048"},{"key":"ref4","unstructured":"World Health Organization. WHO Model Lists of Essential Medicines. 2023. Available at: https:\/\/www.who.int\/groups\/expert-committee-on-selection-and-use-of-essential-medicines\/essential-medicines-lists (Accessed: 25 August 2025)."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Chan ESL, Cronstein BN. Methotrexate\u2013how does it really work? Nature Reviews. Rheumatology. 2010; 6: 175\u2013178.","DOI":"10.1038\/nrrheum.2010.5"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Bedoui Y, Guillot X, S\u00e9lambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al. Methotrexate an Old Drug with New Tricks. International Journal of Molecular Sciences. 2019; 20: 5023.","DOI":"10.3390\/ijms20205023"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High-Dose Methotrexate. The Oncologist. 2016; 21: 1471\u20131482.","DOI":"10.1634\/theoncologist.2015-0164"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Sequier L, Caron B, Loeuille D, Honap S, Jairath V, Netter P, et al. Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2024; 60: 686\u2013700.","DOI":"10.1111\/apt.18194"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"McClure S, Haydock R, Su Y, Rick C, Blackburn S, Brooks M, et al. Methotrexate oral or subcutaneous for rheumatoid arthritis (MOOSE): study protocol for a multi-centre randomised trial. Trials. 2025; 26: 495.","DOI":"10.1186\/s13063-025-09020-4"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nol\u00e8 F, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Annals of Oncology. 2002; 13: 73\u201380.","DOI":"10.1093\/annonc\/mdf013"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. Journal of Clinical Oncology. 2011; 29: 825\u2013831.","DOI":"10.1200\/JCO.2010.30.4386"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Cruz-Carreras MT, Chaftari P, Shamsnia A, Guha-Thakurta N, Gonzalez C. Methotrexate-induced leukoencephalopathy presenting as stroke in the emergency department. Clinical Case Reports. 2017; 5: 1644\u20131648.","DOI":"10.1002\/ccr3.1110"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Leit\u00e3o Santos M, Silva S, Moreira A, Ribeiro A. Methotrexate-Induced Stroke-Like Syndrome: A Typical Presentation of a Rare Complication. Cureus. 2023; 15: e40004.","DOI":"10.7759\/cureus.40004"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Raghavendra S, Nair MD, Chemmanam T, Krishnamoorthy T, Radhakrishnan VV, Kuruvilla A. Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. European Journal of Neurology. 2007; 14: 309\u2013314.","DOI":"10.1111\/j.1468-1331.2006.01659.x"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Matsuda M, Kishida D, Kinoshita T, Hineno A, Shimojima Y, Fukushima K, et al. Leukoencephalopathy induced by low-dose methotrexate in a patient with rheumatoid arthritis. Internal Medicine. 2011; 50: 2219\u20132222.","DOI":"10.2169\/internalmedicine.50.5552"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Apiraksattayakul N, Jitprapaikulsan J, Sanpakit K, Kumutpongpanich T. Potential neurotoxicity associated with methotrexate. Scientific Reports. 2024; 14: 18548.","DOI":"10.1038\/s41598-024-69263-0"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. The Lancet. Oncology. 2014; 15: 809\u2013818.","DOI":"10.1016\/S1470-2045(14)70243-8"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Wahid QA, Hamadeh L, McGowan S, Hough R, Vora A, Moorman AV, et al. Acute Neurotoxicity during ALL Therapy Is Associated with Treatment Intensity, Age and Female Sex - an Analysis of SAE Reports from the UKALL 2003 Trial. Blood. 2018; 132: 1379.","DOI":"10.1182\/blood-2018-99-113267"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Mateos MK, Marshall GM, Barbaro PM, Quinn MCJ, George C, Mayoh C, et al. Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia. Haematologica. 2022; 107: 635\u2013643.","DOI":"10.3324\/haematol.2020.268565"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Taylor OA, Brown AL, Brackett J, Dreyer ZE, Moore IK, Mitby P, et al. Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients. Clinical Cancer Research. 2018; 24: 5012\u20135017.","DOI":"10.1158\/1078-0432.CCR-18-0939"},{"key":"ref21","unstructured":"Reddick WE, Glass JO, Helton KJ, Langston JW, Xiong X, Wu S, et al. Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR. American Journal of Neuroradiology. 2005; 26: 1263\u20131269."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Bhojwani D, Bansal R, Wayne AS. Managing therapy-associated neurotoxicity in children with ALL. Hematology. American Society of Hematology. Education Program. 2021; 2021: 376\u2013383.","DOI":"10.1182\/hematology.2021000269"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen TL, Halsey C, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. The Lancet. Oncology. 2016; 17: e231\u2013e239.","DOI":"10.1016\/S1470-2045(16)30035-3"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"\u015aliwa-Tytko P, Kaczmarska A, Lejman M, Zawitkowska J. Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy. International Journal of Molecular Sciences. 2022; 23: 5515.","DOI":"10.3390\/ijms23105515"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Byrnes DM, Vargas F, Dermarkarian C, Kahn R, Kwon D, Hurley J, et al. Complications of Intrathecal Chemotherapy in Adults: Single-Institution Experience in 109 Consecutive Patients. Journal of Oncology. 2019; 2019: 4047617.","DOI":"10.1155\/2019\/4047617"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy. 2003; 49: 92\u2013104.","DOI":"10.1159\/000069773"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Bernini JC, Fort DW, Griener JC, Kane BJ, Chappell WB, Kamen BA. Aminophylline for methotrexate-induced neurotoxicity. Lancet. 1995; 345: 544\u2013547.","DOI":"10.1016\/s0140-6736(95)90464-6"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"De la Riva P, Andres-Mar\u00edn N, Gonzalo-Yubero N, Tainta-Cuezva M, Caminos N, Urtasun-Ocariz M\u00c1, et al. Headache and other complications following intrathecal chemotherapy administration. Cephalalgia. 2017; 37: 1109\u20131110.","DOI":"10.1177\/0333102416668658"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"West J, Ogston S, Foerster J. Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials. PLoS ONE. 2016; 11: e0153740.","DOI":"10.1371\/journal.pone.0153740"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Van Lint JA, Bakker T, Ten Klooster PM, van Puijenbroek EP, Vonkeman HE, Jessurun NT. Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients. Expert Opinion on Drug Safety. 2022; 21: 417\u2013423.","DOI":"10.1080\/14740338.2022.2003328"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology. 2014; 32: 949\u2013959.","DOI":"10.1200\/JCO.2013.53.0808"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Inaba H, Khan RB, Laningham FH, Crews KR, Pui CH, Daw NC. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Annals of Oncology. 2008; 19: 178\u2013184.","DOI":"10.1093\/annonc\/mdm466"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Ayalon I, Friedman S, Binenbaum Y, Oppenheimer N, Shiran S, Grisaru-Soen G, et al. A Case of Methotrexate Neurotoxicity Presented as Status Epilepticus, Encephalopathy, and High Fever. Journal of Investigative Medicine High Impact Case Reports. 2019; 7: 2324709619862311.","DOI":"10.1177\/2324709619862311"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Bowling JM, Stenberg R, Hill A. Aseptic meningitis with status epilepticus following intrathecal methotrexate. JEM Reports. 2023; 2: 100013.","DOI":"10.1016\/j.jemrpt.2023.100013"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Banerjee J, Niinim\u00e4ki R, L\u00e4hteenm\u00e4ki P, Hed Myrberg I, Arola M, Riikonen P, et al. The spectrum of acute central nervous system symptoms during the treatment of childhood acute lymphoblastic leukaemia. Pediatric Blood & Cancer. 2020; 67: e27999.","DOI":"10.1002\/pbc.27999"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Kranj\u010dec I, Raja\u010di\u0107 N, Janji\u0107 T, Kukuruzovi\u0107 M, Jadrijevi\u0107-Cvrlje F, Pavlovi\u0107 M, et al. Acute Neurotoxicity in Children Treated for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: A 10-Year Single-Centre Experience. Children. 2024; 12: 31.","DOI":"10.3390\/children12010031"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Anastasopoulou S, Nielsen RL, Als-Nielsen B, Banerjee J, Eriksson MA, Helenius M, et al. Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes. Haematologica. 2022; 107: 2318\u20132328.","DOI":"10.3324\/haematol.2021.280016"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"de Laat P, Te Winkel ML, Devos AS, Catsman-Berrevoets CE, Pieters R, van den Heuvel-Eibrink MM. Posterior reversible encephalopathy syndrome in childhood cancer. Annals of Oncology. 2011; 22: 472\u2013478.","DOI":"10.1093\/annonc\/mdq382"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Gajjala S, Menon A, Menon A. 556: METHOTREXATE-INDUCED SEIZURES IN AN ADULT. Critical Care Medicine. 2022; 51: 266.","DOI":"10.1097\/01.ccm.0000907952.90150.1e"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Zhao H, Li S, Xie M, Chen R, Lu H, Wen C, et al. Risk of epilepsy in rheumatoid arthritis: a meta-analysis of population based studies and bioinformatics analysis. Therapeutic Advances in Chronic Disease. 2020; 11: 2040622319899300.","DOI":"10.1177\/2040622319899300"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Dhariwal N, Roy Moulik N, Smriti V, Dhamne C, Chichra A, Srinivasan S, et al. Clinico-radiological profile, management and follow-up of methotrexate induced neurotoxicity in children with acute lymphoblastic leukemia. Leukemia & Lymphoma. 2023; 64: 1971\u20131980.","DOI":"10.1080\/10428194.2023.2245093"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Klaassen ILM, Lauw MN, Fiocco M, van der Sluis IM, Pieters R, Middeldorp S, et al. Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: Risk factors and effect on prognosis. Research and Practice in Thrombosis and Haemostasis. 2019; 3: 234\u2013241.","DOI":"10.1002\/rth2.12182"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR. American Journal of Neuroradiology. 2007; 28: 1320\u20131327.","DOI":"10.3174\/ajnr.A0549"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Bond J, Hough R, Moppett J, Vora A, Mitchell C, Goulden N. \u2018Stroke-like syndrome\u2019 caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial. Leukemia. 2013; 27: 954\u2013956.","DOI":"10.1038\/leu.2012.328"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Harris RD, Bernhardt MB, Zobeck MC, Taylor OA, Gramatges MM, Schafer ES, et al. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate. Cancer. 2023; 129: 1287\u20131294.","DOI":"10.1002\/cncr.34646"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Mahoney DH, Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy\u2013a Pediatric Oncology Group study. Journal of Clinical Oncology. 1998; 16: 1712\u20131722.","DOI":"10.1200\/JCO.1998.16.5.1712"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Rubnitz JE, Relling MV, Harrison PL, Sandlund JT, Ribeiro RC, Rivera GK, et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia. 1998; 12: 1176\u20131181.","DOI":"10.1038\/sj.leu.2401098"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Paudyal B, Viets R, Skliut M. A case of low-dose oral methotrexate-induced reversible neurotoxicity. AJNR. American Journal of Neuroradiology. 2010; 31: E77.","DOI":"10.3174\/ajnr.A2191"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Kim JY, Kim ST, Nam DH, Lee JI, Park K, Kong DS. Leukoencephalopathy and disseminated necrotizing leukoencephalopathy following intrathecal methotrexate chemotherapy and radiation therapy for central nerve system lymphoma or leukemia. Journal of Korean Neurosurgical Society. 2011; 50: 304\u2013310.","DOI":"10.3340\/jkns.2011.50.4.304"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Koppen H, Wessels JA, Ewals JAPM, Treurniet FEE. Reversible leukoencephalopathy after oral methotrexate. The Journal of Rheumatology. 2012; 39: 1906\u20131907.","DOI":"10.3899\/jrheum.120152"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Norrell H, Wilson CB, Slagel DE, Clark DB. Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors. Cancer. 1974; 33: 923\u2013932. <923::aid-cncr2820330406>3.0.co;2-z.","DOI":"10.1002\/1097-0142(197404)33:4"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Asato R, Akiyama Y, Ito M, Kubota M, Okumura R, Miki Y, et al. Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate. Cancer. 1992; 70: 1997\u20132004. <1997::aid-cncr2820700732>3.0.co;2-g.","DOI":"10.1002\/1097-0142(19921001)70:7"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Chu WCW, Chik KW, Chan YL, Yeung DKW, Roebuck DJ, Howard RG, et al. White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: longitudinal study with MR imaging and 1H MR spectroscopy. Radiology. 2003; 229: 659\u2013669.","DOI":"10.1148\/radiol.2293021550"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Rijmenams I, Moechars D, Uyttebroeck A, Radwan A, Blommaert J, Deprez S, et al. Age- and Intravenous Methotrexate-Associated Leukoencephalopathy and Its Neurological Impact in Pediatric Patients with Lymphoblastic Leukemia. Cancers. 2021; 13: 1939.","DOI":"10.3390\/cancers13081939"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Cheung YT, Sabin ND, Reddick WE, Bhojwani D, Liu W, Brinkman TM, et al. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. The Lancet. Haematology. 2016; 3: e456\u2013e466.","DOI":"10.1016\/S2352-3026(16)30110-7"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Castellino SM, Ullrich NJ, Whelen MJ, Lange BJ. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. Journal of the National Cancer Institute. 2014; 106: dju186.","DOI":"10.1093\/jnci\/dju186"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Kirchhoff AC, Leisenring W, Krull KR, Ness KK, Friedman DL, Armstrong GT, et al. Unemployment among adult survivors of childhood cancer: a report from the childhood cancer survivor study. Medical Care. 2010; 48: 1015\u20131025.","DOI":"10.1097\/MLR.0b013e3181eaf880"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Saatci D, Thomas A, Botting B, Sutcliffe A. P3 Exploring the impact of childhood cancer on educational achievement \u2013 a systematic review and meta-analysis. Archives of Disease in Childhood. 2019; 104: A1\u2013A2.","DOI":"10.1136\/archdischild-2019-rcpch.3"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Duffner PK. Risk factors for cognitive decline in children treated for brain tumors. European Journal of Paediatric Neurology. 2010; 14: 106\u2013115.","DOI":"10.1016\/j.ejpn.2009.10.005"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Cheung YT, Krull KR. Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review. Neuroscience and Biobehavioral Reviews. 2015; 53: 108\u2013120.","DOI":"10.1016\/j.neubiorev.2015.03.016"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Riva D, Giorgi C, Nichelli F, Bulgheroni S, Massimino M, Cefalo G, et al. Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology. 2002; 59: 48\u201353.","DOI":"10.1212\/wnl.59.1.48"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Sleurs C, Lemiere J, Radwan A, Verly M, Elens I, Renard M, et al. Long-term leukoencephalopathy and neurocognitive functioning in childhood sarcoma patients treated with high-dose intravenous chemotherapy. Pediatric Blood & Cancer. 2019; 66: e27893.","DOI":"10.1002\/pbc.27893"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Hustu HO, Aur RJA. Extramedullary leukaemia. Clinics in Haematology. 1978; 7: 313\u2013337.","DOI":"10.1016\/s0308-2261(78)80008-3"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Cousens P, Waters B, Said JW, Stevens ML. COGNITIVE EFFECTS OF CRANIAL IRRADIATION IN LEUKAEMIA: A SURVEY AND META-ANALYSIS. Journal of Child Psychology and Psychiatry. 1988; 29: 839\u2013852.","DOI":"10.1111\/j.1469-7610.1988.tb00757.x"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Hill FGH, Richards S, Gibson B, Hann I, Lilleyman J, Kinsey S, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). British Journal of Haematology. 2004; 124: 33\u201346.","DOI":"10.1046\/j.1365-2141.2003.04738.x"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Peterson CC, Johnson CE, Ramirez LY, Huestis S, Pai ALH, Demaree HA, et al. A meta-analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. Pediatric Blood & Cancer. 2008; 51: 99\u2013104.","DOI":"10.1002\/pbc.21544"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Halsey C, Buck G, Richards S, Vargha-Khadem F, Hill F, Gibson B. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. Journal of Hematology & Oncology. 2011; 4: 42.","DOI":"10.1186\/1756-8722-4-42"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Waber DP, Turek J, Catania L, Stevenson K, Robaey P, Romero I, et al. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. Journal of Clinical Oncology. 2007; 25: 4914\u20134921.","DOI":"10.1200\/JCO.2007.10.8464"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Phillips NS, Khan RB, Li C, Mirzaei Salehabadi S, Brinkman TM, Srivastava D, et al. Seizures\u2019 impact on cognition and quality of life in childhood cancer survivors. Cancer. 2022; 128: 180\u2013191.","DOI":"10.1002\/cncr.33879"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Harris RD, Taylor OA, Raghubar KP, Matheus Gonzalez M, Zobeck M, Gramatges MM, et al. Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatric Blood & Cancer. 2024; 71: e31169.","DOI":"10.1002\/pbc.31169"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Pryweller JR, Glass JO, Sabin ND, Laningham FH, Li Y, Jacola LM, et al. Characterization of Leukoencephalopathy and Association With Later Neurocognitive Performance in Pediatric Acute Lymphoblastic Leukemia. Investigative Radiology. 2021; 56: 117\u2013126.","DOI":"10.1097\/RLI.0000000000000715"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Krull KR, Cheung YT, Liu W, Fellah S, Reddick WE, Brinkman TM, et al. Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2016; 34: 2644\u20132653.","DOI":"10.1200\/JCO.2015.65.4574"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Montour-Proulx I, Kuehn SM, Keene DL, Barrowman NJ, Hsu E, Matzinger MA, et al. Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. Journal of Child Neurology. 2005; 20: 129\u2013133.","DOI":"10.1177\/08830738050200020901"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Dautzenberg L, Jessurum N, Dautzenberg PLJ, Keijsers CJPW. Reversible Methotrexate-Induced Dementia: A Case Report. Journal of the American Geriatrics Society. 2015; 63: 1273\u20131274.","DOI":"10.1111\/jgs.13517"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Gosavi T, Diong CP, Lim SH. Methotrexate-induced myelopathy mimicking subacute combined degeneration of the spinal cord. Journal of Clinical Neuroscience. 2013; 20: 1025\u20131026.","DOI":"10.1016\/j.jocn.2012.06.018"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Rodrigues PGB, Lima TTD, Duarte FB, N\u00f3brega PR. Myelopathy associated with intrathecal methotrexate. Practical Neurology. 2022; 22: 141\u2013144.","DOI":"10.1136\/practneurol-2021-003154"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Yi Y, Kang HJ, Shin HY, Kim K. Progressive myelopathy mimicking subacute combined degeneration after intrathecal chemotherapy. Journal of Child Neurology. 2015; 30: 246\u2013249.","DOI":"10.1177\/0883073814527157"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, et al. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. American Journal of Hematology. 2017; 92: 155\u2013160.","DOI":"10.1002\/ajh.24611"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Dukenik DB, Soong D, Li W, Madarang E, Watts J, Taylor J. Methotrexate-Induced Subacute Combined Degeneration in Acute Lymphoblastic Leukemia with CNS Relapse May Be Reversible. Hemato. 2023; 4: 311\u2013320.","DOI":"10.3390\/hemato4040025"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Miyoshi T, Kondo T, Nishikori M, Kitawaki T, Kobayashi K, Fujimoto M, et al. Methotrexate-induced subacute myelopathy: a serious but treatable complication. Journal of Clinical and Experimental Hematopathology. 2023; 63: 251\u2013256.","DOI":"10.3960\/jslrt.23041"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Cohen IJ. Prevention of high-dose-methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation. Medical Hypotheses. 2007; 68: 1147\u20131153.","DOI":"10.1016\/j.mehy.2006.04.074"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Lahoti A, Das Pk, Mohapatra S, Naik S, Panigrahi A, Bhuyan B. Methotrexate(MTX) Induced Leukoencephalopathy(LE) and Relation of Vitamin B12, Folate and \/ or Homocysteine Levels with MTX Toxicity: A Prospective Study. Blood. 2021; 138: 4374.","DOI":"10.1182\/blood-2021-153241"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. The Journal of Clinical Investigation. 1993; 92: 2675\u20132682.","DOI":"10.1172\/JCI116884"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Quinn CT, Griener JC, Bottiglieri T, Hyland K, Farrow A, Kamen BA. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. Journal of Clinical Oncology. 1997; 15: 2800\u20132806.","DOI":"10.1200\/JCO.1997.15.8.2800"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Drachtman RA, Cole PD, Golden CB, James SJ, Melnyk S, Aisner J, et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatric Hematology and Oncology. 2002; 19: 319\u2013327.","DOI":"10.1080\/08880010290057336"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Lipton SA, Kim WK, Choi YB, Kumar S, D\u2019Emilia DM, Rayudu PV, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94: 5923\u20135928.","DOI":"10.1073\/pnas.94.11.5923"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Cole PD, Vijayanathan V, Ali NF, Wagshul ME, Tanenbaum EJ, Price J, et al. Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits. Clinical Cancer Research. 2013; 19: 4446\u20134454.","DOI":"10.1158\/1078-0432.CCR-13-1179"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Vijayanathan V, Gulinello M, Ali N, Cole PD. Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. Behavioural Brain Research. 2011; 225: 491\u2013497.","DOI":"10.1016\/j.bbr.2011.08.006"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Gibson EM, Nagaraja S, Ocampo A, Tam LT, Wood LS, Pallegar PN, et al. Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment. Cell. 2019; 176: 43\u201355.e13.","DOI":"10.1016\/j.cell.2018.10.049"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Chen YC, Sheen JM, Wang SC, Hsu MH, Hsiao CC, Chang KA, et al. Methotrexate Neurotoxicity Is Related to Epigenetic Modification of the Myelination Process. International Journal of Molecular Sciences. 2021; 22: 6718.","DOI":"10.3390\/ijms22136718"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Geraghty AC, Gibson EM, Ghanem RA, Greene JJ, Ocampo A, Goldstein AK, et al. Loss of Adaptive Myelination Contributes to Methotrexate Chemotherapy-Related Cognitive Impairment. Neuron. 2019; 103: 250\u2013265.e8.","DOI":"10.1016\/j.neuron.2019.04.032"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Jang A, Petrova B, Cheong TC, Zawadzki ME, Jones JK, Culhane AJ, et al. Choroid plexus-CSF-targeted antioxidant therapy protects the brain from toxicity of cancer chemotherapy. Neuron. 2022; 110: 3288\u20133301.e8.","DOI":"10.1016\/j.neuron.2022.08.009"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Taylor OA, Hockenberry MJ, McCarthy K, Gundy P, Montgomery D, Ross A, et al. Evaluation of Biomarkers of Oxidative Stress and Apoptosis in Patients With Severe Methotrexate Neurotoxicity: A Case Series. Journal of Pediatric Oncology Nursing. 2015; 32: 320\u2013325.","DOI":"10.1177\/1043454214563409"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Welbat JU, Naewla S, Pannangrong W, Sirichoat A, Aranarochana A, Wigmore P. Neuroprotective effects of hesperidin against methotrexate-induced changes in neurogenesis and oxidative stress in the adult rat. Biochemical Pharmacology. 2020; 178: 114083.","DOI":"10.1016\/j.bcp.2020.114083"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Krull KR, Bhojwani D, Conklin HM, Pei D, Cheng C, Reddick WE, et al. Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology. 2013; 31: 2182\u20132188.","DOI":"10.1200\/JCO.2012.46.7944"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Seigers R, Schagen SB, Coppens CM, van der Most PJ, van Dam FSAM, Koolhaas JM, et al. Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behavioural Brain Research. 2009; 201: 279\u2013284.","DOI":"10.1016\/j.bbr.2009.02.025"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Yang M, Kim JS, Kim J, Jang S, Kim SH, Kim JC, et al. Acute treatment with methotrexate induces hippocampal dysfunction in a mouse model of breast cancer. Brain Research Bulletin. 2012; 89: 50\u201356.","DOI":"10.1016\/j.brainresbull.2012.07.003"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Baratto L, Singh SB, Williams SE, Spunt SL, Rosenberg J, Adams L, et al. Detecting High-Dose Methotrexate\u2013Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [18F]FDG PET\/MRI: A Pilot Study. Journal of Nuclear Medicine. 2024; 65: 864\u2013871.","DOI":"10.2967\/jnumed.123.266760"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Levavi H, Khazak A, Rene J, Pail O, Kremyanskaya M, Mascarenhas J, et al. ALL-625 Methotrexate Neurotoxicity in Adult Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 2023; 23: S258.","DOI":"10.1016\/s2152-2650(23)00973-4"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Forster VJ, van Delft FW, Baird SF, Mair S, Skinner R, Halsey C. Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemotherapy and Pharmacology. 2016; 78: 1093\u20131096.","DOI":"10.1007\/s00280-016-3153-0"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Forster VJ, Bell G, Halsey C. Should nitrous oxide ever be used in oncology patients receiving methotrexate therapy? Paediatric Anaesthesia. 2020; 30: 9\u201316.","DOI":"10.1111\/pan.13760"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Harris RD, Taylor OA, Gramatges MM, Hughes AE, Zobeck M, Pruitt S, et al. Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025; 45: 4\u201311.","DOI":"10.1002\/phar.4638"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Halsey C, Escherich G. A \u201cGoldilocks\u201d approach to CNS leukemia is needed. Blood. 2021; 138: 288\u2013289.","DOI":"10.1182\/blood.2021011461"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Hart C, Kinney MO, McCarron MO. Posterior reversible encephalopathy syndrome and oral methotrexate. Clinical Neurology and Neurosurgery. 2012; 114: 725\u2013727.","DOI":"10.1016\/j.clineuro.2011.12.008"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Sadeh M, Toledano H, Cohen IJ. A Comprehensive Review of Neuropsychologic Studies Supports the Concept That Adequate Folinic Acid Rescue Prevents Post Methotrexate Neurotoxicity. Journal of Pediatric Hematology\/Oncology. 2023; 45: 1\u201311.","DOI":"10.1097\/MPH.0000000000002604"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Donaghy R, Singer L, Dixit K. Intrathecal methotrexate, central nervous system toxicity, and response to N-methyl-D-aspartate antagonism: An adult case series. Neuro-Oncology Practice. 2024; 11: 665\u2013669.","DOI":"10.1093\/nop\/npae051"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Afshar M, Birnbaum D, Golden C. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. Pediatric Neurology. 2014; 50: 625\u2013629.","DOI":"10.1016\/j.pediatrneurol.2014.01.048"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. Journal of Clinical Psychopharmacology. 1995; 15: 263\u2013269.","DOI":"10.1097\/00004714-199508000-00005"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Schwartz AR, Pizon AF, Brooks DE. Dextromethorphan-induced serotonin syndrome. Clinical Toxicology. 2008; 46: 771\u2013773.","DOI":"10.1080\/15563650701668625"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Okamoto K, Hashimoto N, Ishizeki K, Nishimura T, Makino S, Takashima A, et al. Dextromethorphan-induced serotonin syndrome leading to rhabdomyolysis and dialysis-requiring acute kidney injury: a case report and review. Renal Replacement Therapy. 2025; 11: 23.","DOI":"10.1186\/s41100-025-00616-9"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Burns JM, Boyer EW. Antitussives and substance abuse. Substance Abuse and Rehabilitation. 2013; 4: 75\u201382.","DOI":"10.2147\/SAR.S36761"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Fustino NJ, Juhl K, Leister J. Dextromethorphan Administration on Day 0 and Day 7 for Secondary Prevention of Methotrexate-induced Neurotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Case Series. Journal of Pediatric Hematology\/oncology. 2021; 43: e284\u2013e287.","DOI":"10.1097\/MPH.0000000000001714"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Razi W, Haque AU, Sadiq H, Ullah R, Jabbar N, Mirza S. Safety and Efficacy of Aminophylline in Intrathecal Methotrexate-related Neurological Toxicity in Large Pediatric Oncology Centre. Journal of the College of Physicians and Surgeons\u2013Pakistan. 2021; 31: 481\u2013484.","DOI":"10.29271\/jcpsp.2021.04.481"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Suwannakot K, Sritawan N, Naewla S, Aranarochana A, Sirichoat A, Pannangrong W, et al. Melatonin Attenuates Methotrexate-Induced Reduction of Antioxidant Activity Related to Decreases of Neurogenesis in Adult Rat Hippocampus and Prefrontal Cortex. Oxidative Medicine and Cellular Longevity. 2022; 2022: 1596362.","DOI":"10.1155\/2022\/1596362"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Sabry NC, Michel HE, Menze ET. Repurposing of erythropoietin as a neuroprotective agent against methotrexate-induced neurotoxicity in rats. Journal of Psychopharmacology. 2025; 39: 147\u2013163.","DOI":"10.1177\/02698811241295379"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Mannan A, Germon ZP, Chamberlain J, Sillar JR, Nixon B, Dun MD. Reactive Oxygen Species in Acute Lymphoblastic Leukaemia: Reducing Radicals to Refine Responses. Antioxidants. 2021; 10: 1616.","DOI":"10.3390\/antiox10101616"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Harris RD, Taylor OA, Gramatges MM, Hughes AE, Zobeck M, Pruitt S, et al. Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. The Oncologist. 2025; 30: oyaf055.","DOI":"10.1093\/oncolo\/oyaf055"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Cole PD, Kim SY, Li Y, Schembri A, Kelly KM, Sulis ML, et al. Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia. Supportive Care in Cancer. 2023; 31: 109.","DOI":"10.1007\/s00520-022-07566-6"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Hardy KK, Kairalla JA, Gioia AR, Weisman HS, Gurung M, Noll RB, et al. Impaired neurocognitive functioning 3 months following diagnosis of high-risk acute lymphoblastic leukemia: A report from the Children\u2019s Oncology Group. Pediatric Blood & Cancer. 2023; 70: e30350.","DOI":"10.1002\/pbc.30350"}],"container-title":["British Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/6\/10.31083\/BJHM55135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:58:08Z","timestamp":1783421888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/6\/10.31083\/BJHM55135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1750-8460(26)03042-0"],"URL":"https:\/\/doi.org\/10.31083\/bjhm55135","relation":{},"ISSN":["1750-8460","1759-7390"],"issn-type":[{"value":"1750-8460","type":"print"},{"value":"1759-7390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"55135"}}